Oxfordhealthspan

Oxford Healthspan sells a tightly focused line of longevity supplements built around spermidine, fisetin and related natural autophagy activators. Single-bottle prices run US $55-$90, while 3- and 6-month bundles drop the per-bottle cost to the mid-range; everything is sold direct-to-consumer through the brand’s own Shopify site and Amazon storefront, with no brick-and-mortar retail. The company differentiates by sourcing high-purity, 99% spermidine-rich wheat-germ extract from western Europe and publishing third-party Certificates of Analysis for every batch. Founder Leslie Kenny, an Oxford-based autoimmune patient turned biohacker, positions the brand as “evidence-led anti-aging,” translating Japanese and EU geroscience into English-language protocols; its hero SKU, Primeadine®, is one of the few spermidine products standardized to both 1 mg spermidine per capsule and the polyamine cofactors thought to enhance uptake. Core buyers are 35-65-year-old health professionals, quantified-self enthusiasts and peri-menopausal women willing to self-experiment beyond basic vitamins. They value biological-age reversal, open-label data and hormone-free plant compounds, and they typically stack Oxford Healthspan capsules with fasting or NAD+ boosters. The brand competes in the fast-growing cellular-autophagy niche against other single-ingredient longevity start-ups and multi-ingredient “healthy aging” pills sold by larger nutraceutical labs. It counters by spotlighting one hero molecule at a time, publishing human (not just mouse) trial references, and offering batch-level analytics—tactics that position it as a research-first option rather than a broad-spectrum anti-aging cocktail.